Latest Pharma Insights
Reckitt Seizes OTC Growth Opportunity In Emerging Markets
Reckitt's leadership discussed the company's growth strategy for emerging markets at a recent meeting for analysts.
HBW Insight - December 11, 2025
Reckitt's leadership discussed the company's growth strategy for emerging markets at a recent meeting for analysts.
HBW Insight - December 11, 2025
Cipla Launches Second Tirzepatide As Wegovy Price Cuts Tighten Gap With Mounjaro
Cipla’s rollout of Lilly’s tirzepatide second brand comes as Wegovy price cuts tighten competition in India’s fast-growing GLP-1 market.
Generics Bulletin - December 11, 2025
Cipla’s rollout of Lilly’s tirzepatide second brand comes as Wegovy price cuts tighten competition in India’s fast-growing GLP-1 market.
Generics Bulletin - December 11, 2025
Council And Parliament Reach Deal On EU Pharma Legislation Reform
Responding to the newly-agreed EU pharma package, Medicines for Europe said the deal was a limited political compromise that could have been more ambitious – particularly when it comes to access – but nevertheless represented “an important step forward” and “progress” for the EU pharma sector.
Generics Bulletin - December 11, 2025
Responding to the newly-agreed EU pharma package, Medicines for Europe said the deal was a limited political compromise that could have been more ambitious – particularly when it comes to access – but nevertheless represented “an important step forward” and “progress” for the EU pharma sector.
Generics Bulletin - December 11, 2025
Novartis Taps Relation To Boost AI-Driven Drug Discovery In Immuno-Dermatology
The deal, which could be worth as much as $1.7bn, looks to use Relation's AI capabilities to power the discovery of potentially first-in-class immuno-dermatology targets.
Scrip - December 11, 2025
The deal, which could be worth as much as $1.7bn, looks to use Relation's AI capabilities to power the discovery of potentially first-in-class immuno-dermatology targets.
Scrip - December 11, 2025
US Government Fights Hikma’s Corner In Skinny Label Vascepa Row
“Section viii cannot function as Congress intended,” if a Federal Circuit ruling stands, the US solicitor general has argued as he urged the Supreme Court to review and reverse the closely-watched Hikma skinny-label Vascepa case.
Generics Bulletin - December 11, 2025
“Section viii cannot function as Congress intended,” if a Federal Circuit ruling stands, the US solicitor general has argued as he urged the Supreme Court to review and reverse the closely-watched Hikma skinny-label Vascepa case.
Generics Bulletin - December 11, 2025
Latest Regulatory Updates From The EU As Change Is In The Air
A new face seconded to the European Commission's medtech unit and changes to several EU rules impacting medtech
Medtech Insight - December 11, 2025
A new face seconded to the European Commission's medtech unit and changes to several EU rules impacting medtech
Medtech Insight - December 11, 2025
Supplement Registration And Pre-DSHEA Lists: Key Missing Tools Limiting US Pre-Market Review
FDA looks to Congress for authority to require registration for all supplements available for sale in US for public-facing product listing but no authority can produce list of dietary ingredients available pre-DSHEA.
HBW Insight - December 11, 2025
FDA looks to Congress for authority to require registration for all supplements available for sale in US for public-facing product listing but no authority can produce list of dietary ingredients available pre-DSHEA.
HBW Insight - December 11, 2025
Aerogen’s Vibrating Nebulizer Could Be Breakthrough For Premature Infants
Aerogen, which is Ireland’s largest native medical technology firm, is in clinical trials for Aerofact, a nebulizer aimed at aiding premature infants' breathing. The technology promises easier administration of surfactant, with potential commercial rollout projected in three to four years, if succes
Medtech Insight - December 11, 2025
Aerogen, which is Ireland’s largest native medical technology firm, is in clinical trials for Aerofact, a nebulizer aimed at aiding premature infants' breathing. The technology promises easier administration of surfactant, with potential commercial rollout projected in three to four years, if succes
Medtech Insight - December 11, 2025
Novartis Taps Relation To Boost AI-Driven Drug Discovery In Immuno-Dermatology
The deal, which could be worth as much as $1.7bn, looks to use Relation's AI capabilities to power the discovery of potentially first-in-class immuno-dermatology targets.
Scrip - December 11, 2025
The deal, which could be worth as much as $1.7bn, looks to use Relation's AI capabilities to power the discovery of potentially first-in-class immuno-dermatology targets.
Scrip - December 11, 2025
Latest Regulatory Updates From The EU As Change Is In The Air
A new face seconded to the European Commission's medtech unit and changes to several EU rules impacting medtech
Medtech Insight - December 11, 2025
A new face seconded to the European Commission's medtech unit and changes to several EU rules impacting medtech
Medtech Insight - December 11, 2025
Aerogen’s Vibrating Nebulizer Could Be Breakthrough For Premature Infants
Aerogen, which is Ireland’s largest native medical technology firm, is in clinical trials for Aerofact, a nebulizer aimed at aiding premature infants' breathing. The technology promises easier administration of surfactant, with potential commercial rollout projected in three to four years, if succes
Medtech Insight - December 11, 2025
Aerogen, which is Ireland’s largest native medical technology firm, is in clinical trials for Aerofact, a nebulizer aimed at aiding premature infants' breathing. The technology promises easier administration of surfactant, with potential commercial rollout projected in three to four years, if succes
Medtech Insight - December 11, 2025
Reckitt Seizes OTC Growth Opportunity In Emerging Markets
Reckitt's leadership discussed the company's growth strategy for emerging markets at a recent meeting for analysts.
HBW Insight - December 11, 2025
Reckitt's leadership discussed the company's growth strategy for emerging markets at a recent meeting for analysts.
HBW Insight - December 11, 2025
Supplement Registration And Pre-DSHEA Lists: Key Missing Tools Limiting US Pre-Market Review
FDA looks to Congress for authority to require registration for all supplements available for sale in US for public-facing product listing but no authority can produce list of dietary ingredients available pre-DSHEA.
HBW Insight - December 11, 2025
FDA looks to Congress for authority to require registration for all supplements available for sale in US for public-facing product listing but no authority can produce list of dietary ingredients available pre-DSHEA.
HBW Insight - December 11, 2025
Cipla Launches Second Tirzepatide As Wegovy Price Cuts Tighten Gap With Mounjaro
Cipla’s rollout of Lilly’s tirzepatide second brand comes as Wegovy price cuts tighten competition in India’s fast-growing GLP-1 market.
Generics Bulletin - December 11, 2025
Cipla’s rollout of Lilly’s tirzepatide second brand comes as Wegovy price cuts tighten competition in India’s fast-growing GLP-1 market.
Generics Bulletin - December 11, 2025
Council And Parliament Reach Deal On EU Pharma Legislation Reform
Responding to the newly-agreed EU pharma package, Medicines for Europe said the deal was a limited political compromise that could have been more ambitious – particularly when it comes to access – but nevertheless represented “an important step forward” and “progress” for the EU pharma sector.
Generics Bulletin - December 11, 2025
Responding to the newly-agreed EU pharma package, Medicines for Europe said the deal was a limited political compromise that could have been more ambitious – particularly when it comes to access – but nevertheless represented “an important step forward” and “progress” for the EU pharma sector.
Generics Bulletin - December 11, 2025
US Government Fights Hikma’s Corner In Skinny Label Vascepa Row
“Section viii cannot function as Congress intended,” if a Federal Circuit ruling stands, the US solicitor general has argued as he urged the Supreme Court to review and reverse the closely-watched Hikma skinny-label Vascepa case.
Generics Bulletin - December 11, 2025
“Section viii cannot function as Congress intended,” if a Federal Circuit ruling stands, the US solicitor general has argued as he urged the Supreme Court to review and reverse the closely-watched Hikma skinny-label Vascepa case.
Generics Bulletin - December 11, 2025
German Giants Rise Up The Ranks In Generics Bulletin’s Top 50
Two leading German generics and biosimilars giants are the big movers at the top of our annual ranking of off-patent industry leaders. We reveal the latest developments in this year’s Generics Bulletin Top 50.
In Vivo - December 10, 2025
Two leading German generics and biosimilars giants are the big movers at the top of our annual ranking of off-patent industry leaders. We reveal the latest developments in this year’s Generics Bulletin Top 50.
In Vivo - December 10, 2025
Europe Leads Charge As Private Equity Roars Back Into Off-Patent Pharma
A pair of private equity mega-deals dominated the mergers and acquisitions landscape in 2025, but there was still a clear appetite for smaller, strategic takeovers and tuck-ins across the generics, biosimilars, and off-patent medicines field.
In Vivo - December 10, 2025
A pair of private equity mega-deals dominated the mergers and acquisitions landscape in 2025, but there was still a clear appetite for smaller, strategic takeovers and tuck-ins across the generics, biosimilars, and off-patent medicines field.
In Vivo - December 10, 2025
Execs On The Move: November 2025
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
In Vivo - December 10, 2025
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
In Vivo - December 10, 2025
Indegene Exec On R&D Operations In The Age Of GenAI, One Click Submissions
Senior Indegene executive discusses why pharma R&D organizations of the future will need to be agile, modular and AI-native by design. Industry pilots are pointing the way to potential one click regulatory submissions.
In Vivo - December 10, 2025
Senior Indegene executive discusses why pharma R&D organizations of the future will need to be agile, modular and AI-native by design. Industry pilots are pointing the way to potential one click regulatory submissions.
In Vivo - December 10, 2025
Podcast: Kairos Pharma’s Approach To Resensitizing Tumors
In this episode of the In Vivo podcast, Kairos Pharma's chief scientific officer discusses developing therapies to reverse drug resistance in oncology, with ENV-105 showing promising Phase II results in resensitizing hormone-resistant prostate cancer.
In Vivo - December 10, 2025
In this episode of the In Vivo podcast, Kairos Pharma's chief scientific officer discusses developing therapies to reverse drug resistance in oncology, with ENV-105 showing promising Phase II results in resensitizing hormone-resistant prostate cancer.
In Vivo - December 10, 2025